We are rapidly advancing ONS-5010, a uniquely positioned anti-VEGF therapy for ophthalmic indications

Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a complex, technically challenging and commercially attractive monoclonal antibody, or mAb, for various ophthalmic indications.

Our goal is to launch ONS-5010 as the first, and only, approved bevacizumab in the United States, Europe, Japan and other markets for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO).

About ONS-5010

ONS-5010 is an innovative mAb therapeutic currently enrolling patients in a clinical trial outside the United States designed to serve as the first of two adequate and well controlled studies evaluating ONS-5010 for wet AMD.

We plan to submit an investigational new drug, or IND, application with the U.S. Food and Drug Administration, or FDA, in the first quarter of calendar 2019 and the U.S. portion of the second study is scheduled to begin at that time. Our ONS-5010 wet AMD clinical program was reviewed at a successful end of Phase 2 meeting with the FDA conducted in 2018. If the program is successful, it will support our plans to submit for regulatory approval in multiple markets in 2020.

Because there are no approved bevacizumab products for the treatment of retinal diseases, we are developing ONS-5010 as an innovative therapy and not using the biosimilar drug development pathway.


Through skill and experience, our team expertly handles the challenges of mAb development